Y-PEG IFN- α 2a / Xiamen Amoytop Biotech, BioGeneric Pharma - LARVOL DELTA

Age, fibrosis and diabetic status, but not ethnicity, influences therapeutic response in Greek and Egyptian treatment-naïve patients infected with hepatitis C genotype 4 (EASL 2012) - Presentation time: 21.04.2012, 09:00-18:00; N=177; Overall, SVR was achieved by 75/177 (42.4%) of the cohort without significant difference between the two ethnic groups [Greek: 44/101 (43.6%); Egyptian 31/76 (40.8%), p=0.7598]

Retrospective data • Hepatitis C Virus

Safety, dosage and efficacy of a novel Y shaped molecule of pegylated interferon alpha 2a for treatment of chronic HCV (AASLD 2011) - Presentation time: Nov 07 8:00 AM - 5:30 PM; P=NA, N=84; Commonly reported adverse effects are hemoglobin drop below 10 gm% in 6 (23%), 7 (23%), & 3 patients (11%) respectively (p=0.39), a low neutrophilic count (<750) in 3 (11.1%) in group A, 5 (16.7%) in group B & only one patient (3.6%) in group C (p=0.27); Complete early virological response was 96%, 87% & 79% in groups A, B & C respectively (p=0.16)

Clinical data